Drug intelligence / Profile preview

granotapide

Development stage: Phase 2
Lead developer: Japan Tobacco
Modality: Small Molecules
Administration: Oral

Overview

Granotapide is an orally active small molecule drug that functions as a microsomal triglyceride transfer protein (MTP) inhibitor. It has been investigated primarily for the treatment of type II diabetes mellitus and hyperlipidemia. By inhibiting MTP, granotapide reduces the absorption of cholesterol and triglycerides from the intestine and impairs the assembly and secretion of plasma lipoproteins containing apolipoprotein B. This mechanism leads to decreased lipid levels in circulation, which may benefit patients with metabolic disorders such as diabetes and hyperlipidemia[1][2][3][7]. The drug was developed by Japan Tobacco.

Brand names: granotapide
Other names: granotapideJTT-130JTT130JTT 130594842-13-4PSZ2YGB0DKPSZ-2YGB0DKPSZ 2YGB0DK

Targets

MTTP (Microsomal triglyceride transfer protein large subunit)

Beyond the preview

Go deeper on granotapide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on granotapide.

Explore the full profile